A Phase 1/2 interventional study of Advate (Low Dose) and Advate (High Dose) in Hemophilia A, sponsored by Bioverativ, a Sanofi company. Completed at 10 sites in 2 countries. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-04-19.
Sponsored by Bioverativ, a Sanofi company (part of Sanofi) · Phase 1/2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing efanesoctocog alfa in Hemophilia A — 1 open to participants now, 5 under way, 2 of them phase 3. efanesoctocog alfa · Hemophilia A.
Among the 11 studies testing efanesoctocog alfa in Hemophilia A, this one is the 10th largest by enrollment, is the only one that started in 2017, is the only one in phase 1/2, and was the 1st registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →1 of the 11 studies testing efanesoctocog alfa in Hemophilia A is open now, in 5 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Australia, Canada and 2 more countries
Ages 12+
By country, each count listing its studies:
efanesoctocog alfa: first FDA approval 2023 (ALTUVIIIO), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 65 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1 · Phase 3 5 · Phase 4 3
First in 2017; this study’s year is marked. 1 started in 2017.
This study's enrollment of 16 is below the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 74 across the 11 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 3 most frequent:
This study is registered under Bioverativ, a Sanofi company, one of the names counted as Sanofi. Under that name alone:
Bioverativ, a Sanofi company is the lead sponsor of 16 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 7 (58%) have results posted.
29 studies in Hemophilia A by Sanofi: 4 open now, 8 under way, 3 of them phase 3. Of 21 finished, 14 (67%) have results posted.
Among the 29 studies in Hemophilia A by Sanofi, this one is the 21st largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2017, is one of 2 in phase 1/2, and was the 12th registered.
Sanofi’s Hemophilia A studies by the year they started, since 2009.
4 of the studies testing efanesoctocog alfa in Hemophilia A that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04644575Phase 3Bioverativ, a Sanofi companyLong-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A | 2027-01-15 |
| NCT06716814Phase 3Swedish Orphan BiovitrumStudy to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa | 2027-03 |
| NCT06752850Swedish Orphan BiovitrumA Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis | 2026-11-17 |
| NCT06941870SanofiEfanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy | 2027-10-25 |
Add all 4 to your calendar (.ics) → With an account.
Among the 11 studies testing efanesoctocog alfa in Hemophilia A, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 29 in Hemophilia A:
This tab as a report to print or save as PDF → With an account.
The primary purpose was to assess the safety and tolerability of a single intravenous (IV) administration of BIVV001 in adult previously treated patients (PTPs) with severe hemophilia A.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medical History:
Medications and Procedures:
Other:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single intravenous (IV) dose of Advate 25 international units per kilogram (IU/kg) on Day 1 of Advate treatment period (3 days) followed by a single IV dose of BIVV001 25 IU/kg in BIVV001 treatment period (BTP) (28 days). Advate treatment period (ATP) consisted of a washout of at least 72 hours which was started from the time of Advate dosing.
Biological: Advate (Low Dose) · Biological: BIVV001 (Low Dose)
Participants received a single IV dose of Advate 65 IU/kg on Day 1 of ATP (4 days) followed by a single IV dose of BIVV001 65 IU/kg in BTP (28 days). ATP consisted of a washout of at least 96 hours which was started from the time of Advate dosing.
Biological: Advate (High Dose) · Biological: BIVV001 (High Dose)
Participants received a single IV low dose of Advate 25 IU/kg.
Participants received a single IV high dose of Advate 65 IU/kg.
Participants received single IV low dose of BIVV001 25 IU/kg.
Participants received single IV high dose of BIVV001 65 IU/kg.
Number of Participants With Treatment Emergent Adverse Events (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) During Advate Treatment Period
AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAE is defined as any AE that begins on or after the single dose of Advate but before the single dose of BIVV001. Serious AE (SAE) was defined as any AE resulting in death, immediate risk of death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, or a congenital/anomaly/birth defect, or any other medically important event.
Time frame: Up to Day 3 for Advate 25 IU/kg; up to Day 4 for Advate 65 IU/kg
Number of Participants With Treatment Emergent Adverse Events (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) During BIVV001 Treatment Period
AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAE is defined as any AE that begins on or after the study treatment (BIVV001) and within 28 days after BIVV001 administration. SAE was defined as any AE resulting in death, immediate risk of death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, or a congenital/anomaly/birth defect, or any other medically important event.
Time frame: Up to 28 days after BIVV001 administration
Number of Participants With Clinically Significant Abnormalities in Laboratory Tests During Advate Treatment Period
Number of Participants with Clinically Significant Abnormalities in Laboratory tests (including hematology, clinical chemistry, urinalysis, and coagulation and thrombosis markers) was reported.
Time frame: Up to Day 3 for Advate 25 IU/kg; up to Day 4 for Advate 65 IU/kg
Number of Participants With Clinically Significant Abnormalities in Laboratory Tests During BIVV001 Treatment Period
Number of participants with clinically significant abnormalities (including hematology, clinical chemistry, urinalysis, and coagulation and thrombosis markers) was reported.
Time frame: Up to 28 days after BIVV001 administration
Percentage of Participants With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
Development of an inhibitor was defined as a neutralizing antibody value of greater than or equal to (\>=) 0.6 Bethesda units per milliliter (BU/mL) identified and confirmed by a second test on an independent sample, collected within 2 to 4 weeks of the first positive sample, with both tests performed by the central laboratory using Nijmegen-modified Bethesda assay.
Time frame: Up to 28 days after BIVV001 administration
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) for Advate and BIVV001 (Low Dose Comparison)
Cmax of Advate and BIVV001 at low dose was assessed and compared based on One-stage activated partial thromboplastin time (aPTT)-based clotting assay.
Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours
PK: Maximum Observed Plasma Concentration (Cmax) for Advate and BIVV001 (High Dose Comparison)
Cmax of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.
Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours
PK: Half-Life (t1/2) for Advate and BIVV001 (Low Dose Comparison)
Half-life is defined as time required for the concentration of the drug to reach half of its original value. t1/2 of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.
Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours
PK: Half-Life for Advate and BIVV001 (High Dose Comparison)
Half-life is defined as time required for the concentration of the drug to reach half of its original value. t1/2 of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.
Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours
PK: Total Body Clearance (CL) for Advate and BIVV001 (Low Dose Comparison)
Clearance is defined as a quantitative measure of the rate at which a drug substance is removed from the body. CL of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.
Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours
PK: Total Body Clearance (CL) for Advate and BIVV001 (High Dose Comparison)
Clearance is defined as a quantitative measure of the rate at which a drug substance is removed from the body. CL of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.
Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours
PK: Volume of Distribution at Steady State (Vss) for Advate and BIVV001 (Low Dose Comparison)
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vss of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.
Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours
PK: Volume of Distribution at Steady State (Vss) for Advate and BIVV001 (High Dose Comparison)
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vss of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.
Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours
PK: Area Under the Concentration Time Curve (AUC) From Time 0 to Infinity (AUCinfinity) for Advate and BIVV001 (Low Dose Comparison)
AUCinfinity of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.
Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours
PK: Area Under the Concentration Time Curve From Time 0 to Infinity (AUCinfinity) for Advate and BIVV001 (High Dose Comparison)
AUCinfinity of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.
Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours
PK: Mean Residence Time (MRT) for Advate and BIVV001 (Low Dose Comparison)
The average time at which the number of absorbed molecules reside in the body, after single-dose administration. MRT of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.
Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours
PK: Mean Residence Time (MRT) for Advate and BIVV001 (High Dose Comparison)
The average time at which the number of absorbed molecules reside in the body, after single-dose administration. MRT of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.
Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours
PK: Incremental Recovery (IR) for Advate and BIVV001 (Low Dose Comparison)
Incremental Recovery is defined as the increase in the circulating FVIII activity level for one unit (IU) of the FVIII product per kilogram body weight. IR of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.
Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours
PK: Incremental Recovery (IR) for Advate and BIVV001 (High Dose Comparison)
Incremental Recovery is defined as the increase in the circulating FVIII activity level for one unit (IU) of the FVIII product per kilogram body weight. IR of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.
Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours
PK: Time to 1% Above Baseline for FVIII Activity for Advate and BIVV001 (Low Dose Comparison)
Time to 1% activity is the time required from the start of dosing for the FVIII activity to reach 1 IU/dL (1%) above their baseline levels. Time to 1% above baseline for FVIII Activity of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.
Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, and 240 hours
PK: Time to 1% Above Baseline for FVIII Activity for Advate and BIVV001 (High Dose Comparison)
Time to 1% activity is the time required from the start of dosing for the FVIII activity to reach 1 IU/dL (1%) above their baseline levels. Time to 1% above baseline for FVIII Activity of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.
Time frame: For Advate: Pre-dose and Post dose at 0.5, 1, 6, 24, 48, and 72 hours; For BIVV001: Pre-dose and Post dose at 0.17, 0.5, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168, 240, 288, and 336 hours
The study was conducted in Japan and United States between 28 August 2017 to 12 November 2018.
| Milestone | Low Dose Cohort (LDC): Advate 25 IU/kg Then BIVV001 25 IU/kg | High Dose Cohort (HDC): Advate 65 IU/kg Then BIVV001 65 IU/kg |
|---|---|---|
| Started | 7 | 9 |
| Safety population | 7 | 9 |
| Completed | 6 | 9 |
| Not completed | 1 | 0 |
| Withdrew: Sponsor decision | 1 | 0 |
| Milestone | Low Dose Cohort (LDC): Advate 25 IU/kg Then BIVV001 25 IU/kg | High Dose Cohort (HDC): Advate 65 IU/kg Then BIVV001 65 IU/kg |
|---|---|---|
| Started | 6 | 9 |
| Safety population | 6 | 9 |
| Completed | 6 | 9 |
| Not completed | 0 | 0 |
AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAE is defined as any AE that begins on or after the single dose of Advate but before the single dose of BIVV001. Serious AE (SAE) was defined as any AE resulting in death, immediate risk of death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, or a congenital/anomaly/birth defect, or any other medically important event.
| Participants | Advate 25 IU/kg | Advate 65 IU/kg |
|---|---|---|
| TEAE | 2 | 1 |
| TESAE | 1 | 0 |
AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAE is defined as any AE that begins on or after the study treatment (BIVV001) and within 28 days after BIVV001 administration. SAE was defined as any AE resulting in death, immediate risk of death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, or a congenital/anomaly/birth defect, or any other medically important event.
| Participants | BIVV001 25 IU/kg | BIVV001 65 IU/kg |
|---|---|---|
| TEAE | 3 | 6 |
| TESAE | 1 | 0 |
Number of Participants with Clinically Significant Abnormalities in Laboratory tests (including hematology, clinical chemistry, urinalysis, and coagulation and thrombosis markers) was reported.
| Participants | Advate 25 IU/kg | Advate 65 IU/kg |
|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Laboratory Tests During Advate Treatment Period | 0 | 0 |
Number of participants with clinically significant abnormalities (including hematology, clinical chemistry, urinalysis, and coagulation and thrombosis markers) was reported.
| Participants | BIVV001 25 IU/kg | BIVV001 65 IU/kg |
|---|---|---|
| Number of Participants With Clinically Significant Abnormalities in Laboratory Tests During BIVV001 Treatment Period | 0 | 0 |
Development of an inhibitor was defined as a neutralizing antibody value of greater than or equal to (\>=) 0.6 Bethesda units per milliliter (BU/mL) identified and confirmed by a second test on an independent sample, collected within 2 to 4 weeks of the first positive sample, with both tests performed by the central laboratory using Nijmegen-modified Bethesda assay.
| percentage of participants | Low Dose Cohort (LDC): Advate 25 IU/kg Then BIVV001 25 IU/kg | High Dose Cohort (HDC): Advate 65 IU/kg Then BIVV001 65 IU/kg |
|---|---|---|
| Percentage of Participants With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay | 0 | 0 |
Cmax of Advate and BIVV001 at low dose was assessed and compared based on One-stage activated partial thromboplastin time (aPTT)-based clotting assay.
| International unit/deciliter (IU/dL) | Advate 25 IU/kg | BIVV001 25 IU/kg |
|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) for Advate and BIVV001 (Low Dose Comparison) | 51.8 (43.3 to 61.9) | 70.1 (49.7 to 98.9) |
Cmax of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.
| IU/dL | Advate 65 IU/kg | BIVV001 65 IU/kg |
|---|---|---|
| PK: Maximum Observed Plasma Concentration (Cmax) for Advate and BIVV001 (High Dose Comparison) | 138 (117 to 162) | 161 (142 to 183) |
Half-life is defined as time required for the concentration of the drug to reach half of its original value. t1/2 of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.
| hours | Advate 25 IU/kg | BIVV001 25 IU/kg |
|---|---|---|
| PK: Half-Life (t1/2) for Advate and BIVV001 (Low Dose Comparison) | 9.12 (6.24 to 13.33) | 37.61 (33.28 to 42.50) |
Half-life is defined as time required for the concentration of the drug to reach half of its original value. t1/2 of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.
| hours | Advate 65 IU/kg | BIVV001 65 IU/kg |
|---|---|---|
| PK: Half-Life for Advate and BIVV001 (High Dose Comparison) | 13.15 (10.89 to 15.87) | 42.54 (39.72 to 45.56) |
Clearance is defined as a quantitative measure of the rate at which a drug substance is removed from the body. CL of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.
| milliliter/hour/kilogram (mL/hr/kg) | Advate 25 IU/kg | BIVV001 25 IU/kg |
|---|---|---|
| PK: Total Body Clearance (CL) for Advate and BIVV001 (Low Dose Comparison) | 3.91 (3.05 to 5.02) | 0.558 (0.411 to 0.757) |
Clearance is defined as a quantitative measure of the rate at which a drug substance is removed from the body. CL of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.
| mL/hr/kg | Advate 65 IU/kg | BIVV001 65 IU/kg |
|---|---|---|
| PK: Total Body Clearance (CL) for Advate and BIVV001 (High Dose Comparison) | 3.31 (2.81 to 3.88) | 0.505 (0.436 to 0.586) |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vss of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.
| milliliter/kilogram (mL/kg) | Advate 25 IU/kg | BIVV001 25 IU/kg |
|---|---|---|
| PK: Volume of Distribution at Steady State (Vss) for Advate and BIVV001 (Low Dose Comparison) | 55.9 (51.2 to 61.0) | 34.8 (27.3 to 44.3) |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vss of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.
| mL/kg | Advate 65 IU/kg | BIVV001 65 IU/kg |
|---|---|---|
| PK: Volume of Distribution at Steady State (Vss) for Advate and BIVV001 (High Dose Comparison) | 58.3 (49.8 to 68.2) | 35.0 (29.7 to 41.1) |
AUCinfinity of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.
| hour*international unit/deciliter | Advate 25 IU/kg | BIVV001 25 IU/kg |
|---|---|---|
| PK: Area Under the Concentration Time Curve (AUC) From Time 0 to Infinity (AUCinfinity) for Advate and BIVV001 (Low Dose Comparison) | 638 (495 to 822) | 4470 (3280 to 6080) |
AUCinfinity of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.
| hour*international unit/deciliter | Advate 65 IU/kg | BIVV001 65 IU/kg |
|---|---|---|
| PK: Area Under the Concentration Time Curve From Time 0 to Infinity (AUCinfinity) for Advate and BIVV001 (High Dose Comparison) | 1960 (1670 to 2310) | 12800 (11100 to 14900) |
The average time at which the number of absorbed molecules reside in the body, after single-dose administration. MRT of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.
| hours | Advate 25 IU/kg | BIVV001 25 IU/kg |
|---|---|---|
| PK: Mean Residence Time (MRT) for Advate and BIVV001 (Low Dose Comparison) | 12.54 (9.82 to 16.01) | 56.93 (49.19 to 65.89) |
The average time at which the number of absorbed molecules reside in the body, after single-dose administration. MRT of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.
| hours | Advate 65 IU/kg | BIVV001 65 IU/kg |
|---|---|---|
| PK: Mean Residence Time (MRT) for Advate and BIVV001 (High Dose Comparison) | 15.66 (14.06 to 17.45) | 67.66 (62.59 to 73.14) |
Incremental Recovery is defined as the increase in the circulating FVIII activity level for one unit (IU) of the FVIII product per kilogram body weight. IR of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.
| IU/dL per IU/kg | Advate 25 IU/kg | BIVV001 25 IU/kg |
|---|---|---|
| PK: Incremental Recovery (IR) for Advate and BIVV001 (Low Dose Comparison) | 2.0 (1.60 to 2.50) | 2.72 (1.95 to 3.80) |
Incremental Recovery is defined as the increase in the circulating FVIII activity level for one unit (IU) of the FVIII product per kilogram body weight. IR of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.
| IU/dL per IU/kg | Advate 65 IU/kg | BIVV001 65 IU/kg |
|---|---|---|
| PK: Incremental Recovery (IR) for Advate and BIVV001 (High Dose Comparison) | 2.11 (1.79 to 2.49) | 2.48 (2.18 to 2.82) |
Time to 1% activity is the time required from the start of dosing for the FVIII activity to reach 1 IU/dL (1%) above their baseline levels. Time to 1% above baseline for FVIII Activity of Advate and BIVV001 at low dose was assessed and compared based on One-stage aPTT-based clotting assay.
| hours | Advate 25 IU/kg | BIVV001 25 IU/kg |
|---|---|---|
| PK: Time to 1% Above Baseline for FVIII Activity for Advate and BIVV001 (Low Dose Comparison) | 56.97 (49.25 to 65.89) | 260.53 (222.34 to 305.30) |
Time to 1% activity is the time required from the start of dosing for the FVIII activity to reach 1 IU/dL (1%) above their baseline levels. Time to 1% above baseline for FVIII Activity of Advate and BIVV001 at high dose was assessed and compared based on One-stage aPTT-based clotting assay.
| hours | Advate 65 IU/kg | BIVV001 65 IU/kg |
|---|---|---|
| PK: Time to 1% Above Baseline for FVIII Activity for Advate and BIVV001 (High Dose Comparison) | 78.48 (70.88 to 86.89) | 350.34 (326.61 to 375.81) |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to end of the study (28 days after BIVV001 administration) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Advate Dose Level: 25 IU/kg | 0/7 (0%) | 1/7 (14.3%) | 1/7 (14.3%) |
| Advate Dose Level: 65 IU/kg | 0/9 (0%) | 0/9 (0%) | 1/9 (11.1%) |
| BIVV001 Dose Level: 25 IU/kg | 0/6 (0%) | 1/6 (16.7%) | 3/6 (50%) |
| BIVV001 Dose Level: 65 IU/kg | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| Event | Advate Dose Level: 25 IU/kg | Advate Dose Level: 65 IU/kg | BIVV001 Dose Level: 25 IU/kg | BIVV001 Dose Level: 65 IU/kg |
|---|---|---|---|---|
| Small intestinal obstructionGastrointestinal disorders | 0/7 | 0/9 | 1/6 | 0/9 |
| ContusionInjury, poisoning and procedural complications | 1/7 | 0/9 | 0/6 | 0/9 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/7 | 0/9 | 0/6 | 0/9 |
| HaemarthrosisMusculoskeletal and connective tissue disorders | 1/7 | 0/9 | 0/6 | 0/9 |
| TendonitisMusculoskeletal and connective tissue disorders | 1/7 | 0/9 | 0/6 | 0/9 |
| Event | Advate Dose Level: 25 IU/kg | Advate Dose Level: 65 IU/kg | BIVV001 Dose Level: 25 IU/kg | BIVV001 Dose Level: 65 IU/kg |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/7 | 0/9 | 1/6 | 0/9 |
| Gingival painGastrointestinal disorders | 0/7 | 0/9 | 1/6 | 0/9 |
| Thrombin-antithrombin iii complex increasedInvestigations | 1/7 | 1/9 | 1/6 | 1/9 |
| Pain in jawMusculoskeletal and connective tissue disorders | 0/7 | 0/9 | 1/6 | 0/9 |
| HeadacheNervous system disorders | 0/7 | 0/9 | 1/6 | 1/9 |
| Coagulation test abnormalInvestigations | 1/7 | 0/9 | 0/6 | 0/9 |
| PalpitationsCardiac disorders | 0/7 | 0/9 | 0/6 | 1/9 |
| NasopharyngitisInfections and infestations | 0/7 | 0/9 | 0/6 | 1/9 |
| Viral upper respiratory tract infectionInfections and infestations | 0/7 | 0/9 | 0/6 | 1/9 |
| Joint injuryInjury, poisoning and procedural complications | 0/7 | 0/9 | 0/6 | 1/9 |
Baseline population included all enrolled participants.
| Age, Continuous(years) | LDC: Advate 25 IU/kg Then BIVV001 25 IU/kg | HDC: Advate 65 IU/kg Then BIVV001 65 IU/kg | Total |
|---|---|---|---|
| Mean | 33.0 ± 13.81 | 44.0 ± 11.65 | 39.2 ± 13.43 |
| Sex: Female, Male(Participants) | LDC: Advate 25 IU/kg Then BIVV001 25 IU/kg | HDC: Advate 65 IU/kg Then BIVV001 65 IU/kg | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 7 | 9 | 16 |
| Race (NIH/OMB)(Participants) | LDC: Advate 25 IU/kg Then BIVV001 25 IU/kg | HDC: Advate 65 IU/kg Then BIVV001 65 IU/kg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 6 | 7 | 13 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Aug 2017 to primary completion in Nov 2018, 14 months.
Results were first posted in Dec 2019, 1 year after primary completion.
Of 20 phase 1/2 interventional studies under Hemophilia A, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 94. This study's 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efanesoctocog alfa
Bioverativ, a Sanofi company →